Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Moberg Pharma

8.97 SEK

-0.39 %

Less than 1K followers

MOB

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-0.39 %
-15.30 %
-0.33 %
0.00 %
-11.80 %
-42.83 %
-44.05 %
-75.28 %
-84.99 %

Moberg Pharma is a Swedish pharmaceutical company with a focus on commercialization of proprietary drugs based on proven substances. The company works primarily in nail fungus, where Moberg Pharma is developing a topical treatment. Moberg Pharma has agreements with commercial partners in place in Europe and Canada, among other places. The company's headquarters are located in Bromma.

Read more
Market cap
436.95M SEK
Turnover
481.34K SEK
Revenue
9.81M
EBIT %
-3,311.21 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.2
2026

Annual report '25

12.5
2026

Interim report Q1'26

21.5
2026

General meeting '26

All
Press releases
ShowingAll content types
Press release11/14/2025, 11:32 AM

Redeye: Moberg Pharma (Q3 Review) - European footprint expanded, strengthening mid-/long-term outlook

Moberg Pharma
Regulatory press release11/11/2025, 7:00 AM

Moberg Pharma interim report January - September 2025

Moberg Pharma
Regulatory press release11/5/2025, 7:30 AM

Moberg Pharma and Karo Healthcare enter exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential

Moberg Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release10/31/2025, 7:30 AM

Moberg Pharma's Nomination Committee appointed

Moberg Pharma
Regulatory press release9/29/2025, 12:00 PM

Bulletin from Moberg Pharma's Extraordinary General Meeting held on 29 September 2025

Moberg Pharma
Regulatory press release9/3/2025, 6:00 AM

Notice of extraordinary general meeting in Moberg Pharma AB (publ)

Moberg Pharma
Press release9/3/2025, 5:59 AM

Moberg Pharma to Expand Board of Directors and Withdraw Share Issue Authorization

Moberg Pharma
Press release8/13/2025, 9:48 AM

Redeye: Moberg Pharma - Terclara is the market leader in both Sweden and Norway

Moberg Pharma
Regulatory press release8/12/2025, 6:00 AM

Moberg Pharma: Interim report January - June 2025

Moberg Pharma
Regulatory press release6/30/2025, 6:00 AM

New number of shares and votes in Moberg Pharma AB (publ)

Moberg Pharma
Regulatory press release6/25/2025, 6:00 AM

Changes to Moberg Pharma's Management

Moberg Pharma
Regulatory press release6/16/2025, 6:00 AM

Moberg Pharma: Terclara market leader also in Norway

Moberg Pharma
Regulatory press release6/3/2025, 11:30 AM

Moberg Pharma: The board of directors exercises authorizations to issue and repurchase C-shares, and converts class C shares to common shares

Moberg Pharma
Regulatory press release5/22/2025, 4:45 PM

Bulletin from Moberg Pharma's AGM on May 22[th], 2025

Moberg Pharma
Press release5/14/2025, 9:17 AM

Redeye: Moberg Pharma Q1 - In the midst of the high season

Moberg Pharma
Regulatory press release5/13/2025, 6:00 AM

Moberg Pharma interim report January - March 2025

Moberg Pharma
Regulatory press release4/22/2025, 6:00 AM

Notice of Annual General Meeting in Moberg Pharma AB (publ)

Moberg Pharma
Regulatory press release4/11/2025, 6:00 AM

Moberg Pharma's Annual report for 2024

Moberg Pharma
Press release2/12/2025, 9:37 AM

Redeye: Moberg Pharma Q4’2024 - All eyes on the European market

Moberg Pharma
Regulatory press release2/11/2025, 7:00 AM

Moberg Pharma Year-end report 2024

Moberg Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.